Pez m98 neo c met

For knockdown of c‐Met, c‐Met shRNA expression vector (PGPU6/GFP/neo‐shRNA‐c‐Met, designated as sh‐Met) and the control vector PGPU6/GFP/neo‐shControl (designated as sh‐NC) were provided by GenePharma Inc (Shanghai, China). c‐Met shRNA sequences are listed in Table S2. For overexpression of c‐Met (Accession NO.: NM_000245), c‐Met overexpression vector (pEZ/M98/neo‐c‐Met, designated as ex‐Met) and the control vector (pEZ/M98/neo‐control, designated as ex‐NC) were provided by GeneCopoeia Inc (Guangzhou, China). All the vectors were transfected by Lipofectamine 2000 (Invitrogen) reagent according to the manufacturer's instructions. Transfection efficiency was confirmed by Western blotting detection of c‐Met expression.

MiR-206 mimics, inhibitors and corresponding controls were chemically synthesized by GenePharma Inc (Shanghai, China). Sequences of miR-206 mimics, inhibitor and corresponding controls were showed as follows: miR-206 mimics: S: 5′-UGG AAG UAA GGA AGU GUG UGG-3′; A:5′-ACA CAC UUC CUU ACA UUC CAU U-3′;Mimics negative control: S:5′-UUC UCC GAA CGU GUC ACG UTT-3′; A:5′-ACG UGA CAC GUU CGG AGA ATT-3′; miR-206 inhibitors: 5′-CCA CAC ACU UCC UUA CAU UCC A – 3′; Inhibitors negative control: 5′-CAG UAC UUU UGU GUA GUA CAA-3′. c-Met (Accession NO.: NM_000245) overexpression vector (pEZ/M98/neo-c-Met, designated as ex-Met) and the control vector (pEZ/M98/neo-control, designated as ex-NC) were provided by genecopoeia Inc (Guangzhou, China).